Hinjiranandana (Somdej Pranangchao Sirikit Hospital, Chonburi); P. Layangool (Bhumibol Adulyadej Hospital, Bangkok); N. Kamonpakorn (Somdej Prapinklao Hospital, Bangkok); S. Buranabanjasatean (Mae Chan Hospital, Chiang Rai); C. Ngampiyaskul (Prapokklao Provincial Hospital, Chantaburi); T. Chotpitayasunondh, S. Chanpradub and P. Leawsrisuk (Queen Sirikit National Institute of Protease Inhibitor Library supplier Child Health, Bangkok); S. Chearskul, N. Vanprapar, W. Phongsamart, K. Lapphra, P. Chearskul, O. Wittawatmongkol, W. Prasitsuebsai, K. Intalapaporn, N. Kongstan,
N. Pannin, A. Maleesatharn and B. Khumcha (Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University); L. Aurpibul, N. Wongnum and R. Nadsasarn [Research Institute for Health Sciences (RIHES), Chiang Mai University, Chiang Mai]; P. Lumbiganon, P. Tharnprisan and T. Udompanich (Department of Pediatrics, Faculty of Medicine, Khon Kaen University); M. Yentang (Petchburi Hospital, Petchburi); A. Khonponoi, N. Maneerat, S. Denjunta, S. Watanaporn, C. Yodsuwan, W. Srisuk, Volasertib concentration S. Somsri and K. Surapanichadul (Chiang Rai Regional Hospital, Chiang Rai). The authors would like to acknowledge
Dr. Nneka Edwards-Jackson for her help with manuscript preparation. “
“The aim of the study was to explore the awareness of rectal microbicides, the use of pre-exposure prophylaxis (PREP) and the willingness to participate in biomedical HIV prevention trials in a cohort of HIV-negative gay men. In a community-based cohort study, HIV-negative homosexually active men in Sydney, Australia were questioned about awareness of rectal microbicides, use of PREP, and willingness to participate
in trials of such products. Predictors of awareness and willingness to participate were analysed by logistic regression. Use of PREP was examined prospectively. Overall, 14% had heard of rectal microbicides. Older (P=0.05) and 4��8C university-educated men (P=0.001) were more likely to have knowledge of rectal microbicides. Almost one-quarter (24%) of men reported that they were likely/very likely to participate in rectal microbicide trials. Among those men with definite opinions on participation, awareness of rectal microbicides was significantly associated with unwillingness to participate [odds ratio (OR) 0.78, 95% confidence interval (CI) 0.65–0.93, P=0.007]. Willingness to participate in trials using antiretroviral drugs (ARVs) to prevent HIV infection was reported by 43% of men, and was higher among those who reported unprotected anal intercourse (UAI) with HIV-positive partners (OR 1.88, 95% CI 0.99–3.56).